The present study aims to compare vaccination-induced PAbs with combinations of registered MAbs attending to their differential impact on HER1 and HER2 downregulation, subsequent inhibition of signaling through these receptors, and impairment of cell viability in tumor lines that are models of resistance to HER1-targeting therapies. Here, ERBB2 is linked to neoplasm.